30 closest matches · ranked by relevance
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
Allergic Rhinitis · Asthma · Food Allergy
Primary: Wheal Response — 6.8 mm
Allergic Rhinitis · Allergic Conjunctivitis
Primary: The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo. — 0.461; 0.464 cm2 — p=0.57
History of IgE Dependent Reaction to a Penicillin Product
Primary: Negative Predictive Value — 98.0 percentage of participants
Dermatitis, Eczematous
Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants
Allergy Drug · Allergic Reaction · Pediatric
Primary: True Allergy (Consistent With an IgE-mediated Reaction) — 135 Allergies
Allergic Skin Reaction
Primary: Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) — 0 participants
Penicillin Allergy
Primary: Number of Respondents Who Responded YES to Any Question Defining High Risk Penicillin Allergy Using Questionnaire Developed by the Study — 36; 36 Participants
Allergy Skin · Allergic Skin Reaction
Primary: Wheal Measurement — 0; 7.91; 0.32 mm
Contact Dermatitis
Primary: Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21 — 78.9 percentage of concordant responses
Allergy Skin · Allergy · Dermatitis, Allergic Contact
Primary: Wheal Formation — .85; 6.68; .2 mm
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
Contact Dermatitis
Primary: Classification of Test Site Region Reaction — 1247; 163; 1126; 284 Skin Patch Interpretations
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
Hookworm Infection · Allergy
Primary: 100 Mcg/ml Na-ASP-2 Prick-puncture Skin Test — 0 Units on a scale
Immune System Diseases
Primary: Sensitivity for 100 HEP/mL — 75; 0 positive reaction
Contact Dermatitis
Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants
Allergic Rhinoconjunctivitis
Primary: Number and Seriousness of Both Local and Systemic Adverse Reactions — 2; 1; 0; 1 adverse reactions number
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Allergy
Primary: Evidence of Pre-Existing Sensitization by Use of the Erythemal Scoring Scale (ESS) — 0 percentage of patients w allergic rxn
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Birch Pollen Allergy
Primary: Treatment Emergent Adverse Events — 13; 3; 81; 2 number of adverse events per arm
Contact Dermatitis
Primary: Number of Participants With Positive Patch Test Responses — 14; 12; 11; 0 participants
Asthma
Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units
Food Allergy
Primary: Desensitisation — 7; 5; 2 Participants
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
Immunotherapy · Allergy
Primary: Change in Patient Pain Perception Utilizing Three Non-pharmacological Pain Control / Distraction Devices and Ethyl Chloride Spray — 1.33; 2.22; 2.25; 1.45 score on a scale
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019